Xiaoting Wang Ph.D.

Xiaoting Wang PhD, RAC, is currently serving as the Senior Director of Regulatory Affairs at Entrada Therapeutics, focusing on strategy and execution for lead programs in Duchenne Muscular Dystrophy (DMD). Previously, Xiaoting held the position of Director of Regulatory Affairs at AbbVie/ImmunoGen, leading global regulatory efforts for a novel antibody drug conjugate and guiding the team through a successful FDA Breakthrough Therapy designation. Experience also includes roles as Associate Director at Kowa Research Institute and Regulatory Affairs Manager at Jazz Pharmaceuticals, where Xiaoting was instrumental in multiple IND and NDA submissions. Xiaoting's early career involved research and regulatory roles at Duke University and other organizations. Educational credentials include a PhD in Neuroscience from Rosalind Franklin University and a Master's in Botany from Nanjing University, along with a Certificate in Regulatory Affairs from San Diego State University.